Department of Gynecology Oncology, University Hospital of Canary Islands, Avda. Marítima del Sur s/n, Las Palmas de Gran Canaria, Spain.
Eur J Obstet Gynecol Reprod Biol. 2010 Dec;153(2):188-92. doi: 10.1016/j.ejogrb.2010.07.024. Epub 2010 Aug 21.
To evaluate the clinical outcome and pathological features of patients with borderline ovarian tumors (BOT) with special emphasis on serous and mucinous histology.
Medical and anatomopathological records were reviewed in the Gynecological Oncology Department of the Canarian University Hospital between 1990 and 2005. Survival rates were analyzed by using the Kaplan-Meier technique.
The study included 163 patients. Serous tumors corresponded to 68 cases and mucinous tumors to 91 cases. Eighty-nine percent of patients were at FIGO stage I, 1.2% at stage II and 9.8% at stage III. Serous histology was significantly related to the presence of peritoneal implants (22.4% vs 3.6%; p=0.001), positive peritoneal cytology (35.7% vs 8.5%; p=0.001) and bilaterality (27.9% vs 1.1%, p<0.0001). Event-free survival (EFS) rates at 2, 5 and 10 years were 96.7%, 92.7% and 90.5%, respectively, with a mean survival time of 183 months (CI 95% 172-193). Thirteen recurrence cases were found (7.9%) with a mean time to recurrence of 39.6 months (range 4-140). Overall survival (OS) rates at 2, 5 and 10 years were 100%, 96.4% and 93.6%, respectively, with a mean time of 189 months (CI 95% 179-198). Mucinous BOT were associated with significantly lower OS rates than serous BOT (10 years OS: 88.5% vs 98.2%; p=0.01).
Serous tumors present more unfavorable anatomopathological characteristics but are associated with better prognosis than mucinous tumors. If mucinous BOT diagnosis is retained physicians should be aware that their aggressive potential is not negligible.
评估特殊强调浆液性和黏液性组织学的交界性卵巢肿瘤（BOT）患者的临床结果和病理特征。
1990 年至 2005 年期间，在加那利群岛大学医院妇科肿瘤科审查了医疗和解剖病理学记录。使用 Kaplan-Meier 技术分析生存率。
研究包括 163 例患者。浆液性肿瘤 68 例，黏液性肿瘤 91 例。89%的患者处于 FIGO 分期 I 期，1.2%处于 II 期，9.8%处于 III 期。浆液性组织学与腹膜种植（22.4%对 3.6%；p=0.001）、阳性腹膜细胞学（35.7%对 8.5%；p=0.001）和双侧性（27.9%对 1.1%，p<0.0001）显著相关。2 年、5 年和 10 年无事件生存率（EFS）分别为 96.7%、92.7%和 90.5%，平均生存时间为 183 个月（95%CI 172-193）。发现 13 例复发病例（7.9%），复发时间平均为 39.6 个月（范围 4-140）。2 年、5 年和 10 年总生存率（OS）分别为 100%、96.4%和 93.6%，平均时间为 189 个月（95%CI 179-198）。黏液性 BOT 的 OS 率明显低于浆液性 BOT（10 年 OS：88.5%对 98.2%；p=0.01）。
浆液性肿瘤具有更不利的解剖病理学特征，但与黏液性肿瘤相比具有更好的预后。如果保留黏液性 BOT 的诊断，医生应该意识到其侵袭性潜力不容忽视。
